Skip to main content
Premium Trial:

Request an Annual Quote

InterVenn Biosciences Closes $201M Series C Round

NEW YORK – Glycoproteomics firm InterVenn Biosciences said Monday that it has closed a $201 million Series C financing round.

South San Francisco-based InterVenn said it planned to use the funds for the development and commercialization of its Dawn liquid biopsy assay for predicting patient response to immune checkpoint inhibitors and to expand its base of users for its glycoproteomics platform.

The round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, and Highside Capital Management, with participation from previous investors Amplify Partners, Anzu Partners, Genoa Ventures, and True Ventures. Cowen served as sole placement agent to InterVenn for the round.

"With this fundraising, we believe InterVenn is ideally positioned to unlock the glycoproteome as a novel and fundamental layer in biology, which will reveal a myriad of new insights on how to diagnose and treat disease," Aldo Carrascoso, InterVenn's cofounder and CEO, said in a statement.

The new financing follows a $34 million Series B round the company raised last year. At that time, InterVenn was planning to commercialize an ovarian cancer diagnostic test, as well as develop its immuno-oncology treatment response test and a colorectal cancer screening test.

For an in-depth look at InterVenn's plans following its financing, click here.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.